Scientists at The Wistar Institute have discovered that a class of FDA-approved cancer drugs known as PARP1 inhibitors can effectively combat Epstein-Barr virus (EBV)-driven lymphomas. The findings, ...

Real-world data suggest that Erleada may offer an advantage over other treatment options for patients with metastatic ...

Associations between hormone therapy and young-onset breast cancer (diagnosed at younger than 55 years) vary, according to a study published online in the July issue of The Lancet Oncology. Katie M. O ...

The Trump administration's broadsides against scientific research have caused unprecedented upheaval at the National Cancer ...

The last time it was announced that Mary Beckerle would be leaving the Huntsman Cancer Institute, there was uproar. But this ...

The turmoil at the National Institutes of Health's largest arm under the Trump administration could slow progress in the ...

Mary Beckerle, PhD, plans to step down as CEO of Huntsman Cancer Institute, part of Salt Lake City-based University of Utah Health, effective Sept. 1. Dr. Beckerle has served as CEO since 2006, ...

Mary Beckerle is stepping down from her long tenure as CEO of Huntsman Cancer Institute at the University of Utah. Beckerle ...

Indian American biomedical researcher has reported novel biomarkers for colorectal, bladder, prostate, stomach and pancreatic ...